CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2- breast cancer: A meta-analysis of randomized controlled trials

Breast J. 2020 Jul;26(7):1439-1443. doi: 10.1111/tbj.13703. Epub 2019 Dec 11.
No abstract available

Keywords: abemaciclib; breast cancer; palbociclib; ribociclib.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Cyclin-Dependent Kinase 4
  • Female
  • Humans
  • Piperazines
  • Randomized Controlled Trials as Topic

Substances

  • Piperazines
  • CDK4 protein, human
  • Cyclin-Dependent Kinase 4